

CANNSUN MEDHEL GROUP PLC ANNOUNCES ADDITIONS TO ITS BOARD AND STRENGTHENS WOMEN'S HEALTH DIVISION

DUBLIN, IRELAND, October 14, 2020 /EINPresswire.com/ -- Cannsun Medhel Group PLC ("Cannsun" or the "Company"), a 103 year old Biopharmaceutical company focused on developing and commercializing new medicines to optimize human potential with operations in South Africa, Greece, Thailand and Lesotho, today announced the nomination of Dr. Lola Ohonba to their Board of Directors adding medical expertise in cannabis pharmacology and health related products. Dr. Ohonba strengthens our pharmaceutical and Women's Health Division and will support our R&D in cannabinoid product development and related treatments.



Dr. Lola Ohonba

Dr. Lola Ohonba, Director. Born and raised in Nigeria, Dr. Ohonba moved to the United States for her studies and is a clinical registered Pharmacist in Florida and Texas. Dr. Ohonba attended Texas Southern University obtaining her degree in Biology and minor in Chemistry, later

"

We are very excited to have Dr. Ohonba join our team as she brings a strong African and female perspective of medicine to our board" David Parry obtaining her Doctor of Pharmacy from the Union University in Jackson, Tennessee. Dr. Ohonba has extensive experience in patient care and spent several years as staff pharmacist for a major retail pharmacy chain. Most recently she worked as a clinical pharmacist working with commercial clients and responsible for prior authorization, appeals, grievances for Medicare & Medicaid. Dr. Ohonba is a certified medical cannabis professional with a passion for botanical medicine. She is committed to educating the

public on cannabis/hemp and the treatments related to central nervous disorders such as

anxiety, depression and pain.

"The appointment of Dr. Ohonba provides a strong fundamental background in prescription medicine, cannabinoids and a passion for helping people which will help drive the development of our Women's Health division. We are very excited to have Dr. Ohonba join our team as she brings a strong African and female perspective of medicine to our board. Women's health and wellness are key areas of focus for Cannsun and Dr. Ohonba will be a key individual for our greater success." commented President and Chief Executive Officer of Cannsun Medhel David Parry.

For more information on women's health and our current product line click the link below.

https://cannsunmedhel.com/women/

About Medhel

First established in 1918 and now with new management and ownership, Cannsun is reemerging as a science-led, global, healthcare company focused on leveraging its existing infrastructure and reputation in the manufacture and distribution of established healthcare products and pharmaceuticals, as well as building a vertically integrated cannabinoid division. The Company currently distributes products to thousands of healthcare professionals and pharmacies in 21 countries. Our current projected growth will enable us to deepen and extend our reach, so that we can help people everywhere live better, healthier lives. www.cannsunmedhel.com

Contact:

Rorisang Ntai Director Phone: +27 82 575 1144 Email: rorisang@cannsun.com[]

Nikolaos Manias Senior Business Development Phone: +30 695 181 0901 Email: n.manias@cannsun.com[]

Greg Bealer Director of Finance Phone: +1 780 970 3789 Email: g.bealer@cannsun.com

David Parry

This press release can be viewed online at: https://www.einpresswire.com/article/528357742

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2020 IPD Group, Inc. All Right Reserved.